The Endocrine and Neuroendocrine Tumor Program offers a multidisciplinary, comprehensive approach for the full spectrum of treatment for these unique tumors. With years of expertise, our specialists offer care for thyroid cancer including medullary thyroid cancer, parathyroid tumors, adrenal tumors and hormone-producing adrenal tumors, pheochromocytoma, paraganglioma, adrenocortical cancer, and carcinoid and neuroendocrine tumors located throughout the body.
Our team of endocrine surgeons, neurosurgeons, surgical oncologists, endocrinologists, medical oncologists, radiation oncologists, radiologists, advanced practice nurses, nurse navigators, social workers, and genetic counselors collaborate to ensure that each patient is cared for with an individualized approach, providing the most advanced treatment options available. Our providers meet weekly to coordinate patient care from diagnosis to treatment to follow-up, providing a close, collaborative approach between specialists.
Since some endocrine and neuroendocrine tumors may occur together within genetic syndromes such as multiple endocrine neoplasia types 1 and 2 (MEN), von Hippel-Lindau syndrome, we offer both genetic counseling and a full spectrum of testing. In addition, we can offer in-office ultrasounds and biopsies as part of the evaluation. Via a patient-centered approach, our program aims to provide the latest in diagnostic and treatment strategies as well as oncology support services throughout the course of treatment.
Our clinicians work closely with our scientists on basic, clinical, and translational research activities in an effort to advance our understanding of these unique tumors. Cutting edge clinical research conducted within the Program provides patients with access to the latest clinical trials and novel therapeutics.
Steve K. Libutti, MD, FACS, was awarded a $1.2 million ‘Petersen Accelerator Award’ from the Neuroendocrine Tumor Research Foundation to pursue work leading to precise treatments for neuroendocrine tumors – an uncommon cancer impacting an estimated 171,000 Americans.